Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Ardelyx (NASDAQ:ARDX) reported strong Q2 2025 financial results, with total revenue of $97.7 million, representing a 33% year-over-year growth. The company's flagship products showed significant performance: IBSRELA generated $65.0 million in net sales (84% YoY growth) and XPHOZAH contributed $25.0 million.
Key financial highlights include a strong cash position of $238.5 million as of June 30, 2025. The company raised its 2025 IBSRELA revenue guidance to $250-$260 million. Despite revenue growth, Ardelyx reported a net loss of $19.1 million ($0.08 per share) for Q2 2025.
Notable developments include securing an option to draw additional debt of $100 million through SLR Investment Corp. and key executive appointments including Mike Kelliher as Chief Business Officer and James P. Brady as Chief Human Resources Officer.
Ardelyx (NASDAQ:ARDX), a biopharmaceutical company focused on developing first-in-class medicines, has scheduled its second quarter 2025 financial results conference call for August 4, 2025, at 4:30 p.m. Eastern Time.
The company will discuss Q2 2025 financial performance and provide business updates. Investors can join via phone at (877) 346-6112 (domestic) or (848) 280-6350 (international). A live webcast will be available on the Investors section of www.ardelyx.com and archived for 30 days after the call.
Ardelyx (NASDAQ: ARDX), a biopharmaceutical company focused on developing first-in-class medicines for unmet medical needs, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025. President and CEO Mike Raab will engage in a fireside chat on June 4, 2025, at 8:10 am ET in New York. The presentation will be accessible via live webcast on the company's website, with a replay available for 30 days following the event.
The IBS in America 2024 survey revealed that higher IBS-C symptom severity correlates with increased financial hardship. The analysis used FACIT-COST® and PROMIS® scales to assess financial toxicity and symptoms.
Safety data from the Phase 3 R-ALLY study in pediatric patients (12-18 years) with IBS-C showed no serious adverse events, with diarrhea being the only drug-related side effect. Additionally, a Phase 1 study demonstrated that tenapanor was not detectable in breast milk of healthy lactating females after repeated administration.
Ardelyx has strengthened its board of directors with the appointment of Merdad Parsey, M.D., Ph.D., a veteran biotech leader with over 25 years of pharmaceutical industry experience. Parsey, who recently retired as Chief Medical Officer at Gilead Sciences in 2025, brings extensive expertise in clinical development and leadership.
His impressive career includes key positions at prominent organizations:
- Chief Medical Officer at Gilead Sciences (2019-2025)
- Senior Vice President of early clinical development at Genentech (2015-2019)
- CEO of 3-V Biosciences (2010-2015)
Parsey's appointment aligns with Ardelyx's mission to develop first-in-class medicines for unmet medical needs. His background in research, early development, and clinical strategy positions him to support the company's growth objectives, including expanding their commercial products and building a robust medicine pipeline.
Ardelyx (Nasdaq: ARDX) has announced the acceptance of three abstracts for poster presentations at the Digestive Disease Week Conference (DDW) in San Diego, May 3-6, 2025. The presentations will showcase data on IBSRELA® (tenapanor), their FDA-approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults.
The three poster presentations will cover:
- Safety and tolerability of tenapanor in pediatric IBS-C patients
- A pharmacokinetic study of tenapanor in breast milk of healthy lactating females
- Correlation between IBS-C symptom severity and financial burden from the IBS in America 2024 survey
Additionally, Ardelyx will sponsor a Product Theater on May 4, featuring Dr. Satish Rao and Christina Hanson, NP, discussing clinical considerations for managing adult IBS-C patients, including efficacy and safety data from Phase 3 trials.
Ardelyx (NASDAQ: ARDX) has scheduled its first quarter 2025 financial results conference call for Thursday, May 1, 2025, at 4:30 p.m. Eastern Time. The biopharmaceutical company will discuss Q1 2025 financial performance and provide a business update during the call.
Investors can participate by dialing (877) 346-6112 (domestic) or (848) 280-6350 (international). A live audio webcast will be available on the Investors section of Ardelyx's website at www.ardelyx.com, with a 30-day replay period following the call.
Ardelyx (NASDAQ: ARDX) announced a post-hoc analysis presentation of the OPTIMIZE Study for XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings in Boston. The study analyzed 330 patients with chronic kidney disease on dialysis with hyperphosphatemia.
XPHOZAH, the first FDA-approved phosphate absorption inhibitor (PAI), is designed to reduce serum phosphorus in adult CKD patients on dialysis as add-on therapy. The analysis revealed that among 40% of patients reporting diarrhea, those using loperamide had lower discontinuation rates (9.7%) compared to non-users (24.6%).
The company is also hosting an Exhibitor Showcase on April 11, 2025, focusing on hyperphosphatemia management, where Dr. Vincent Carsillo will discuss XPHOZAH's mechanism of action, efficacy, and safety data from Phase 3 trials.